Kayne Anderson Rudnick Investment Management
DAWN

Kayne Anderson Rudnick Investment Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5
Closed – – 675
2021
Q4 		$0 Buy
+5
New +$103 ﹤0.01% 641

Other funds holding DAWN

CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's DAWN Position: Q1 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2022, closing a stake of 5 shares.

Kayne Anderson Rudnick Investment Management first reported a position in DAWN in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 66 funds tracked by Wall St. Rank hold DAWN as of Q1 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Day One Biopharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 5 Day One Biopharmaceuticals shares in Q1 2022.
  • Kayne Anderson Rudnick Investment Management first reported a position in Day One Biopharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Day One Biopharmaceuticals position peaked at $0 in Q4 2021.
  • 66 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q1 2022, filed 16 May 2022.